Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

28 Nov 2011 10:09

RNS Number : 8783S
Phytopharm PLC
28 November 2011
Β 

Β 

Annex DTR3

Β 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

Β 

Β 

All relevant boxes should be completed in block capital letters.

Β 

1.

Name of the issuer

PHYTOPHARM PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

(III)

(iii) BOTH (i) AND (ii)

3.

Name of person discharging managerial

responsibilities/director

MR ROGER HICKLING, RESEARCH AND DEVELOPMENT DIRECTOR

Β 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

AS 3 ABOVE

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

AS 3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

OPTIONS OVER ORDINARY SHARES OF 1 PENCE EACH

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

Β 

8.

State the nature of the transaction

Β 

Β 

9.

Number of shares, debentures or financial

instruments relating to shares acquired

Β 

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

Β 

Β 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

Β 

13.

Price per share or value of transaction

Β 

Β 

Β 

14.

Date and place of transaction

Β 

Β 

Β 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

16.

Date issuer informed of transaction

Β 

Β 

Β 

Β 

Β 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

Β 

17.

Date of grant

24 NOVEMBER 2011

Β 

18.

Period during which or date on which exercisable

THESE OPTIONS SHALL BE EXERCISEABLE FROM THE THIRD ANNIVERSARY OF GRANT FOR A PERIOD OF SEVEN YEARS

Β 

19.

Total amount paid (if any) for grant of the option

NIL

20.

Description of shares or debentures involved (class and number)

613,026 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES

Β 

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

6.525 PENCE PER SHARE

Β 

22.

Total number of shares or debentures over which options held following notification

2,858,718 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES

23.

Any additional information

Β 

24.

Name of contact and telephone number for queries

ZOE MCGOWANCOMPANY SECRETARY 01480 437697

Β 

Β 

Name of authorised official of issuer responsible for making notification

ZOE MCGOWAN, COMPANY SECRETARY

Date of notification 28 November 2011

Β 

Β 

Β 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

Β 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSBPBMTMBMTBRB
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.